Clinical Trial Update: A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluated durvalumab as monotherapy and in combination therapy for lymphoma and chronic lymphocytic leukemia, and results were posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Lymphoma

Drugs mentioned

• Durvalumab (durvalumab)

Snippet

Sponsor: Celgene | Conditions: Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-03-18